Canaccord Genuity Maintains Hold on Intercept Pharma, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Hold rating on Intercept Pharma (NASDAQ:ICPT) and lowers the price target from $26 to $12.
May 23, 2023 | 10:51 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Canaccord Genuity maintains Hold rating on Intercept Pharma and lowers price target from $26 to $12.
The lowered price target by Canaccord Genuity analyst Edward Nash indicates a bearish outlook on Intercept Pharma's stock. This could lead to a negative short-term impact on the stock price as investors may adjust their positions based on the new price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100